-
Je něco špatně v tomto záznamu ?
Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome
PL. Antignani, C. Allegra, J. Fareed,
Jazyk angličtina Země Itálie
Typ dokumentu časopisecké články, pozorovací studie
- MeSH
- duplexní dopplerovská ultrasonografie MeSH
- inhibitory faktoru Xa terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- posttrombotický syndrom prevence a kontrola MeSH
- rivaroxaban terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- trombolytická terapie MeSH
- vena femoralis diagnostické zobrazování MeSH
- vena poplitea diagnostické zobrazování MeSH
- výsledek terapie MeSH
- žilní trombóza diagnostické zobrazování farmakoterapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
BACKGROUND: The study was initiated following the observation of complete recanalization of thrombus in subjects with DVT treated with rivaroxaban after 1-2 weeks. The aim of this observational retrospective study was to evaluate clinically and by means of echo color Duplex, the fibrinolytic effect of rivaroxaban in patients with recent and previous DVT. To accomplish this two populations of patients were evaluated. METHODS: Group 1 was comprised of 31 patients (ranging in age 52-73 years) with popliteal-femoral DVT (12 months ago) treated with standard anticoagulant therapy. In these patients, we found a complete superficial femoral recanalization and partial recanalization of the popliteal vein (30% of residual thrombus). The patients had normal creatinine clearance and liver function. The patients were switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. Group 2 was comprised of 22 patients (ranging in age 65-82 years) with previous popliteal-femoral DVT and documented complete common femoral veins recanalization who presented with a recent superficial femoral vein re-thrombosis (1 week before). The patients had normal creatinine clearance and liver function. The patients switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. RESULTS: In group 1, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks of rivaroxaban therapy. In group 2, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks, and the complete recanalization of the acute re-thrombosis of the superficial femoral veins after 2 weeks of rivaroxaban therapy. No adverse events for both groups were observed. CONCLUSIONS: Our results suggest that rivaroxaban could have a pro-fibrinolytic effect not only on recent thrombus but also on organized thrombus that results in a complete recanalization of affected veins. It is proposed that this lytic effect will preserve venous valve structure and lead to a reduction of incidence of post-thrombotic syndrome in rivaroxaban treated patients.
Central European Vascular Forum Praha Czech Republic
Hemostasis and Thrombosis Research Laboratories Loyola University Medical Center Maywood IL USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19034890
- 003
- CZ-PrNML
- 005
- 20191014114745.0
- 007
- ta
- 008
- 191007s2019 it f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.23736/S0392-9590.18.04031-2 $2 doi
- 035 __
- $a (PubMed)30465419
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a it
- 100 1_
- $a Antignani, Pier Luigi $u Vascular Center, Nuova Villa Claudia, Rome, Italy - antignanipl@gmail.com.
- 245 10
- $a Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome / $c PL. Antignani, C. Allegra, J. Fareed,
- 520 9_
- $a BACKGROUND: The study was initiated following the observation of complete recanalization of thrombus in subjects with DVT treated with rivaroxaban after 1-2 weeks. The aim of this observational retrospective study was to evaluate clinically and by means of echo color Duplex, the fibrinolytic effect of rivaroxaban in patients with recent and previous DVT. To accomplish this two populations of patients were evaluated. METHODS: Group 1 was comprised of 31 patients (ranging in age 52-73 years) with popliteal-femoral DVT (12 months ago) treated with standard anticoagulant therapy. In these patients, we found a complete superficial femoral recanalization and partial recanalization of the popliteal vein (30% of residual thrombus). The patients had normal creatinine clearance and liver function. The patients were switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. Group 2 was comprised of 22 patients (ranging in age 65-82 years) with previous popliteal-femoral DVT and documented complete common femoral veins recanalization who presented with a recent superficial femoral vein re-thrombosis (1 week before). The patients had normal creatinine clearance and liver function. The patients switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. RESULTS: In group 1, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks of rivaroxaban therapy. In group 2, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks, and the complete recanalization of the acute re-thrombosis of the superficial femoral veins after 2 weeks of rivaroxaban therapy. No adverse events for both groups were observed. CONCLUSIONS: Our results suggest that rivaroxaban could have a pro-fibrinolytic effect not only on recent thrombus but also on organized thrombus that results in a complete recanalization of affected veins. It is proposed that this lytic effect will preserve venous valve structure and lead to a reduction of incidence of post-thrombotic syndrome in rivaroxaban treated patients.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a inhibitory faktoru Xa $x terapeutické užití $7 D065427
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a vena femoralis $x diagnostické zobrazování $7 D005268
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a vena poplitea $x diagnostické zobrazování $7 D011152
- 650 _2
- $a posttrombotický syndrom $x prevence a kontrola $7 D054070
- 650 _2
- $a rivaroxaban $x terapeutické užití $7 D000069552
- 650 _2
- $a trombolytická terapie $7 D015912
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a duplexní dopplerovská ultrasonografie $7 D018616
- 650 _2
- $a žilní trombóza $x diagnostické zobrazování $x farmakoterapie $7 D020246
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Allegra, Claudio $u Central European Vascular Forum, Praha, Czech Republic.
- 700 1_
- $a Fareed, Jawed $u Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, USA.
- 773 0_
- $w MED00002267 $t International angiology : a journal of the International Union of Angiology $x 1827-1839 $g Roč. 38, č. 1 (2019), s. 17-21
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30465419 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014115209 $b ABA008
- 999 __
- $a ok $b bmc $g 1451550 $s 1073440
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 38 $c 1 $d 17-21 $e 20181120 $i 1827-1839 $m International angiology $n Int Angiol $x MED00002267
- LZP __
- $a Pubmed-20191007